Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28206077 | 0.81 | ALDH1A1 (0.51) | KMT2AALDH1A1IKBKEMCL1SMN1; SMN2 | |
| SCHEMBL354093 | 0.77 | PKM (0.47) | KMT2AALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL14592154 | 0.76 | ALDH1A1 (0.47) | KMT2AALDH1A1IKBKEMCL1SMN1; SMN2 | |
| SCHEMBL14317086 | 0.75 | KMT2A (0.42) | KMT2AALDH1A1IKBKEMCL1SMN1; SMN2 | |
| SCHEMBL13343501 | 0.75 | KMT2A (0.50) | KMT2AALDH1A1IKBKESMN1; SMN2GAA | |
| SCHEMBL22207701 | 0.75 | KMT2A (0.33) | KMT2AALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL20149587 | 0.74 | KMT2A (0.50) | KMT2AALDH1A1IKBKEMCL1SMN1; SMN2 | |
| SCHEMBL5672197 | 0.73 | — | — | |
| SCHEMBL1001730 | 0.73 | — | — | |
| SCHEMBL22207697 | 0.72 | CA12 (0.43) | ALDH1A1SMN1; SMN2GAAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252491-B2 | IL-17A inhibitors | ELI LILLY AND COMPANY (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3908585-B1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | LILLY CO ELI (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-113286795-B | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3908585-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-17 | — | — | EP | disclosed |
| CN-113286795-A | Imidazo [1,2-b ] pyridazine IL-17A inhibitors | 伊莱利利公司 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252491-B2 | IL-17A inhibitors | IL17A, IL2, IL15 | KMT2A 1267/4885ALDH1A1 942/4885IKBKE 19/4885 |
| US-20220073526-A1 | IL-17A INHIBITORS | IL17A, IL2, IL15 | KMT2A 1267/4885ALDH1A1 942/4885IKBKE 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.